PTX Shares Prescient Therapeutics Limited
ASX · ASXLast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
Cell-therapy and oncology platform exposure could benefit from positive clinical updates and partnership interest.
Signal breakdown
- ▸Recent biotech momentum included Prescient among advancing companies.
- ▾Below 50-day MA (-22.8%)
- ▸Volume 1.67× average — accumulation
- ▾Near 52-week low (7.5% of range)
Is PTX a buy right now?
Trend: PTX is trading below the 50-day average (-27.14%), RSI 32 — neutral momentum, with a 3-month return of -37.80%.
Valuation & quality: Prescient Therapeutics Limited trades on forward P/E 5.1, price-to-book 3.64; fundamentals show net margin -202.9%, return on equity -54.7%, revenue growth -26.2% year on year.
Our screen: ACCUMULATE (score 1) — Cell-therapy and oncology platform exposure could benefit from positive clinical updates and partnership interest.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -28.60% | +0.00% | +60.00% | -25.00% | +50.00% | -22.20% | +0.00% | -28.60% |
Fundamentals
Technical signals
About Prescient Therapeutics Limited
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first-in-class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.